Voyager TherapeuticsVYGR
VYGR
About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Employees: 172
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
33% more call options, than puts
Call options by funds: $169K | Put options by funds: $127K
0.45% less ownership
Funds ownership: 63.29% [Q4 2024] → 62.84% (-0.45%) [Q1 2025]
12% less funds holding
Funds holding: 131 [Q4 2024] → 115 (-16) [Q1 2025]
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
40% less capital invested
Capital invested by funds: $196M [Q4 2024] → $117M (-$78.7M) [Q1 2025]
52% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 27
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$30
809%
upside
Avg. target
$30
809%
upside
High target
$30
809%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 809%upside $30 | Buy Reiterated | 8 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.
Neutral
GlobeNewsWire
1 month ago
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier,” was published in Molecular Therapy and can be accessed here.
Negative
Zacks Investment Research
1 month ago
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.20 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Voyager Reports First Quarter 2025 Financial and Operating Results
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg –
Neutral
GlobeNewsWire
1 month ago
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -
Neutral
GlobeNewsWire
2 months ago
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer's disease (AD).
Neutral
Accesswire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NEW YORK, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™